Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 23 (2007), Issue 3, Pages 179-187

A Mononucleotide Markers Panel to Identify hMLH1/hMSH2 Germline Mutations

M. Pedroni,1 B. Roncari,1 S. Maffei,1 L. Losi,2 A. Scarselli,1 C. Di Gregorio,3 M. Marino,1 L. Roncucci,1 P. Benatti,1 G. Ponti,1 G. Rossi,1 M. Menigatti,1 A. Viel,4 M. Genuardi,5 and M. Ponz de Leon1

1Department of Medicine and Medical Specialities, University of Modena and Reggio Emilia, Modena, Italy
2Department of Pathology, University of Modena and Reggio Emilia, Modena, Italy
3Division of Anatomical Pathology, Carpi Hospital, Modena, Italy
4Division of Experimental Oncology I, IRCCS, Aviano, Italy
5Department of Clinical Fysiopathology, Medical Genetics Section, University of Firenze, Italy

Received 13 April 2007; Accepted 13 April 2007

Copyright © 2007 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Hereditary NonPolyposis Colorectal Cancer (Lynch syndrome) is an autosomal dominant disease caused by germline mutations in a class of genes deputed to maintain genomic integrity during cell replication, mutations result in a generalized genomic instability, particularly evident at microsatellite loci (Microsatellite Instability, MSI). MSI is present in 85–90% of colorectal cancers that occur in Lynch Syndrome. To standardize the molecular diagnosis of MSI, a panel of 5 microsatellite markers was proposed (known as the “Bethesda panel”). Aim of our study is to evaluate if MSI testing with two mononucleotide markers, such as BAT25 and BAT26, was sufficient to identify patients with hMLH1/hMSH2 germline mutations. We tested 105 tumours for MSI using both the Bethesda markers and the two mononucleotide markers BAT25 and BAT26. Moreover, immunohistochemical evaluation of MLH1 and MSH2 proteins was executed on the tumours with at least one unstable microsatellite, whereas germline hMLH1/hMSH2 mutations were searched for all cases showing two or more unstable microsatellites.

The Bethesda panel detected more MSI(+) tumors than the mononucleotide panel (49.5% and 28.6%, respectively). However, the mononucleotide panel was more efficient to detect MSI(+) tumours with lack of expression of Mismatch Repair proteins (93% vs 54%). Germline mutations were detected in almost all patients whose tumours showed MSI and no expression of MLH1/MSH2 proteins. No germline mutations were found in patients with MSI(+) tumour defined only through dinucleotide markers. In conclusion, the proposed mononucleotide markers panel seems to have a higher predictive value to identify hMLH1 and hMSH2 mutation-positive patients with Lynch syndrome. Moreover, this panel showed increased specificity, thus improving the cost/effectiveness ratio of the biomolecular analyses.